Xenon to Report Q3 2026 Financial Results on November 9, 2026
Globe Newswire•02/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 2026 results scheduled for November 9, 2026, after U.S. market close
- ➤Business update and financial results presentation set for 4:30pm EST
- ➤Azetukalner remains in late-stage development for epilepsy, major depressive disorder, and bipolar depression
- ➤Phase 1 K(V)7 and Na(V)1.7 pain programs continue in Xenon’s early-stage portfolio
VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026.
Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers
Get started
Create a free account to read the full story.